| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/26/2003 | CN1399573A Use of phthalazine derivatives |
| 02/26/2003 | CN1399559A Micro-cluster liquids and methods of making and using them |
| 02/26/2003 | CN1399549A Ultrafinel-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same |
| 02/26/2003 | CN1399548A Composition for treatment of external secretion disorders |
| 02/26/2003 | CN1398969A Prepn of modification enzyme for earthworm fibrinolysin |
| 02/26/2003 | CN1398898A Extraction and separation process of ash tree flower sporophore polyglycopeptide |
| 02/26/2003 | CN1398896A Hybrid peptide with vascularization inhibiting activity |
| 02/26/2003 | CN1398895A Hypoxic inducing factor-1 relative peptide and its screening |
| 02/26/2003 | CN1398625A Chinese medicine prepn for treating obliterans thromboangitis |
| 02/26/2003 | CN1398624A Chinese medicine prepn for treating varicose vein |
| 02/26/2003 | CN1398602A Medicated tea |
| 02/26/2003 | CN1398592A Medicine composition for treating tumor and cardiac and cerebral vascular diseases |
| 02/26/2003 | CN1398588A Application of arecaline hydrobromide as medicine for arrhythmia |
| 02/26/2003 | CN1102064C Chinese medicine for lowering blood pressure |
| 02/26/2003 | CN1102050C Chinese patent medicine for treating hemicrania-type diseases caused by cerebral vessal |
| 02/26/2003 | CA2419744A1 A novel crystal of n-hydroxy-2(s)-methyl-5-ethoxymethoxy-4(s)-¬n-(4-phenoxyphenylcarbonyl)amino|pentanamide and a method for the preparation thereof and a pharmaceutical agent comprising the same as active ingredient |
| 02/25/2003 | US6525206 Compounds with high monoamine transporter affinity |
| 02/25/2003 | US6525202 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 02/25/2003 | US6525199 Ring coupling, reduction and deprotecting; synthesis of compounds for alleviation and treatment of symptoms due to ischemic diseases |
| 02/25/2003 | US6525196 5HT1 antagonists for antidepressant therapy |
| 02/25/2003 | US6525083 Antidiabetic agents, antilipemic agents, anticholesterol agents |
| 02/25/2003 | US6525072 Prevention and treatment of cellular disorders such as cancer |
| 02/25/2003 | US6525070 Bipiperidine derivatives as modulators of CCR3 activity and as H1 antagonists |
| 02/25/2003 | US6525060 Triazolo(4,5-d)pyrimidine compounds |
| 02/25/2003 | US6525059 Substituted pyrazoles as p38 kinase inhibitors |
| 02/25/2003 | US6525058 1-ethyl methylester 4-((3- (p-(carboxyamidino)phenyl) -2-oxo-5-oxazolidinyl)methyl)-1-piperazineacetate; Gantofiban; antagonistic action to Glycoprotein GPIIb/IIIa receptor; oily base; gantofiban citrate |
| 02/25/2003 | US6525057 Sustained release ranolazine formulations |
| 02/25/2003 | US6525052 Compounds useful as reversible inhibitors of cysteine proteases |
| 02/25/2003 | US6525051 For treating cytokine-induced hypotension, inflammatory bowel disease, cerebral ischemia, arthritis, adult respiratory distress syndrome, asthma |
| 02/25/2003 | US6525048 Aminomethylphenoxymethyl/benzisoxazole substituted azabicyclic compounds; depression, generalized anxiety disorder, obesity, migraine; 2-(5-Fluoro-benzo(d)isoxazol-3-y)-7-(3-morpholin-4-ylmethylphenoxymethyl) -octahydro-pyrido(1,2-a)pyrazine; |
| 02/25/2003 | US6525047 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair |
| 02/25/2003 | US6525045 Positive allosteric AMPA receptor modulators |
| 02/25/2003 | US6525040 4,4-dimethyl-thieno-(3,2-e)-isoselenazine; antioxidants and cytoprotecting |
| 02/25/2003 | US6525025 Controlling apoptosis; cardiovascular disorders; central nervous system disorders |
| 02/25/2003 | US6524840 Polynucleotides, host cell expression systems, the encoded proteins, polypeptides and peptides |
| 02/25/2003 | US6524815 A promoter which is active in the vascular endothelium and to its use for expressing genes of interest in this tissue |
| 02/25/2003 | US6524799 DNA encoding sparc-related proteins |
| 02/25/2003 | US6524795 Diagnostics for cardiovascular disorders |
| 02/25/2003 | US6524785 Perfusion and/or preservation and/or re-perfusion solution during organ transplant |
| 02/25/2003 | US6524583 Inhibit angiogenesis and induce tumor regression, and have improved safety due to their specificity |
| 02/25/2003 | US6524347 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| 02/21/2003 | WO2002020462A1 Benzoic acid derivatives and drugs containing the same as the active ingredient |
| 02/21/2003 | WO2002016354A1 Chromenone derivatives and their use for treating diseases in conjunction with 5-hta1 receptors and/or dopamine d2 receptors |
| 02/21/2003 | WO2002016328A1 Biphenyl derivatives and the use thereof as integrin inhibitors |
| 02/21/2003 | WO2002016323A1 Biphenyl derivatives and the use thereof as integrin inhibitors |
| 02/21/2003 | CA2420208A1 Biphenyl derivatives and their use as integrin inhibitors |
| 02/21/2003 | CA2420206A1 Chromenone derivatives and the use thereof for the treatment of diseases in connection with 5-hta1 receptors and/or dopamine d2 receptors |
| 02/21/2003 | CA2420205A1 Biphenyl derivatives and the use thereof as integrin inhibitors |
| 02/21/2003 | CA2419722A1 Benzoic acid derivatives and drugs containing the same as the active ingredient |
| 02/20/2003 | WO2003014731A2 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 02/20/2003 | WO2003014703A2 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof |
| 02/20/2003 | WO2003014326A2 Isolation and mobilization of stem cells expressing vegfr-1 |
| 02/20/2003 | WO2003014315A2 Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
| 02/20/2003 | WO2003014309A2 Interleukin-1 receptors in the treatment of diseases |
| 02/20/2003 | WO2003014307A2 Antisense modulation of apolipoprotein(a) expression |
| 02/20/2003 | WO2003014301A2 Hprp4s as modifiers of the p53 pathway and methods of use |
| 02/20/2003 | WO2003014300A2 TRPS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 02/20/2003 | WO2003014299A2 SPHKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 02/20/2003 | WO2003014294A2 Tacis and br3 polypeptides and uses thereof |
| 02/20/2003 | WO2003014287A1 Hops extracts, method for the production and use |
| 02/20/2003 | WO2003014163A1 Anti-idiotypic antibodies of hla class i molecules and the use thereof in the preparation of compositions that are designed to inhibit vascular activation |
| 02/20/2003 | WO2003014158A1 Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use |
| 02/20/2003 | WO2003014145A2 Peptides that bind to atherosclerotic lesions |
| 02/20/2003 | WO2003014137A1 Adenosine a3 receptor agonists |
| 02/20/2003 | WO2003014124A1 Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives serving as nmda antagonists |
| 02/20/2003 | WO2003014112A1 Crystal and process for producing the same |
| 02/20/2003 | WO2003014105A1 Bicyclic compound, production and use as hiv inhibitors |
| 02/20/2003 | WO2003014098A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents |
| 02/20/2003 | WO2003014095A1 Acylaminothiazole derivatives, their preparation and therapeutic use |
| 02/20/2003 | WO2003014092A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents |
| 02/20/2003 | WO2003014090A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 02/20/2003 | WO2003014086A1 Process for the preparation of amorphous form of torsemide |
| 02/20/2003 | WO2003014084A1 Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation |
| 02/20/2003 | WO2003014083A1 Spiro compounds |
| 02/20/2003 | WO2003014082A1 Cyclopenta ` b ! indole derivatives as spla2 inhibitors |
| 02/20/2003 | WO2003014075A2 Novel gamma secretase inhibitors |
| 02/20/2003 | WO2003014073A1 Fatty acid compounds, preparation and uses thereof |
| 02/20/2003 | WO2003014064A1 Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists |
| 02/20/2003 | WO2003013609A1 Sustained-release medicines |
| 02/20/2003 | WO2003013606A1 Thrombomodulin-containing medicinal compositions |
| 02/20/2003 | WO2003013590A1 Use of heparin-binding domain of fibronectin for diagnosis and treatment of cancer |
| 02/20/2003 | WO2003013587A1 Compositions for vascular occlusion |
| 02/20/2003 | WO2003013576A1 Regulation of the apj receptor for use in the treatment or prophylaxis of cardiac diseases |
| 02/20/2003 | WO2003013575A1 Modulation of leukocyte-endothelial interactions following ischemia |
| 02/20/2003 | WO2003013571A1 Peptidomimetics of biologically active metallopeptides |
| 02/20/2003 | WO2003013562A1 Artichoke leaf extracts |
| 02/20/2003 | WO2003013550A1 Micronutrient phosphates as dietary and health supplements |
| 02/20/2003 | WO2003013549A2 Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals |
| 02/20/2003 | WO2003013545A1 Novel benzo-fused heterocycles as endothelin antagonisits |
| 02/20/2003 | WO2003013539A1 Neuroprotective drug |
| 02/20/2003 | WO2003013531A1 Phenyl derivatives as factor xa inhibitors |
| 02/20/2003 | WO2003013530A2 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives as nmda antagonists |
| 02/20/2003 | WO2003013517A1 Aminoisoxazole derivatives active as kinase inhibitors |
| 02/20/2003 | WO2003013513A1 Stable emulsion composition |
| 02/20/2003 | WO2003013509A1 N-phenylpyrrole guanidine derivatives as melanocortin reception ligands |
| 02/20/2003 | WO2003013499A2 Drugs for vasculopaties |
| 02/20/2003 | WO2003013498A2 Nitrate ester-cyclodextrin complexes for treating diseases, particularly coronary diseases |
| 02/20/2003 | WO2003013493A1 Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs |
| 02/20/2003 | WO2003013475A1 Injectable foam and novel pharmaceutical applications thereof |
| 02/20/2003 | WO2003013474A1 Nanoparticulate formulations of fenofibrate |